Vis enkel innførsel

dc.contributor.authorShahini, Negar
dc.contributor.authorBjørkelund, Elisabeth
dc.contributor.authorBendz, Christina
dc.contributor.authorMassey, Richard J
dc.contributor.authorSchjalm, Camilla
dc.contributor.authorHalvorsen, Bente
dc.contributor.authorBroch, Kaspar
dc.contributor.authorUeland, Thor
dc.contributor.authorGullestad, Lars
dc.contributor.authorNilsson, Per H.
dc.contributor.authorAukrust, Pål
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorLouwe, Maria Cornelia
dc.date.accessioned2022-03-14T10:38:18Z
dc.date.available2022-03-14T10:38:18Z
dc.date.created2022-01-25T16:08:04Z
dc.date.issued2021
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11250/2985024
dc.description.abstractObjective Dysregulation of the complement system has been described in patients with heart failure (HF). However, data on the alternative pathway are scarce and it is unknown if levels of factor B (FB) and the C3 convertase C3bBbP are elevated in these patients. We hypothesized that plasma levels of FB and C3bBbP would be associated with disease severity and survival in patients with HF. Methods We analyzed plasma levels of FB, C3bBbP, and terminal C5b-9 complement complex (TCC) in 343 HF patients and 27 healthy controls. Results Compared with controls, patients with HF had elevated levels of circulating FB (1.6-fold, p < 0.001) and C3bBbP (1.3-fold, p < 0.001). In contrast, TCC, reflecting the terminal pathway, was not significantly increased (p = 0.15 vs controls). FB was associated with NT-proBNP, troponin, eGFR, and i.e., C-reactive protein. FB, C3bBbP and TCC were not associated with mortality in HF during a mean follow up of 4.3 years. Conclusion Our findings suggest that in patients with HF, the alternative pathway is activated. However, this is not accompanied by activation of the terminal pathway.en_US
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleThe Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failureen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.source.volume12en_US
dc.source.journalFrontiers in Immunologyen_US
dc.identifier.doi10.3389/fimmu.2021.800978
dc.identifier.cristin1989762
dc.relation.projectNorges forskningsråd: 223255en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal